Significant Differences in Biological Parameters between Prodrugs Cleavable by Carboxypeptidase G2 That Generate 3,5-Difluoro-phenol and -aniline Nitrogen Mustards in Gene-Directed Enzyme Prodrug Therapy Systems

Journal of Medicinal Chemistry

Volumn 47, Issue 10, 2004, Pages 2651-2658

  Niculescu Duvaz, I ^a   Scanlon, I ^a   Niculescu Duvaz, D ^a   Friedlos, F ^a   Martin, J ^a   Marais, R ^a   Springer, C J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(2 CHLOROETHYL)(2 MESYLOXYETHYL)AMINO]BENZOYLGLUTAMIC ACID; [3,5 DIFLUORO 4 [BIS(2 CHLOROETHYL)AMINO]PHENYL]CARBAMOYLGLUTAMIC ACID; ANILINE DERIVATIVE; CARBOXYPEPTIDASE G2; CHLORMETHINE DERIVATIVE; PHENOL DERIVATIVE; PRODRUG; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CALCULATION; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; DRUG SYNTHESIS; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REACTION ANALYSIS; STRUCTURE ANALYSIS;

ANILINE MUSTARD; ANIMALS; ANTINEOPLASTIC AGENTS; BENZENE DERIVATIVES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GENE THERAPY; GLUTAMIC ACID; HALF-LIFE; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NITROGEN MUSTARD COMPOUNDS; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS;

EID: 2342519428     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030966w     Document Type: Article

References (27)

1. Senter, P. D.; Springer, C. J. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv. Drug Delivery Rev. 2001, 53, 247-264.
2. Roth, J. A.; Cristiano, R. G. Gene therapy for cancer: what have we done and where are we going? J. Natl. Cancer Inst. 1997, 89, 21-30.
3. Niculescu-Duvaz, I.; Spooner, R.; Marais, R.; Springer, C. J. Gene-directed enzyme prodrug therapy. Bioconjugate Chem. 1998, 9, 4-22.
4. Denny, W. A.; Wilson, W. R. The design of selectively activated anti-cancer prodrugs for use in antibody-directed and gene-directed enzyme prodrugs therapies. J. Pharm. Pharmacol. 1998, 50, 387-394.
5. Springer, C. J.; Niculescu-Duvaz, I. Prodrug-activating systems in suicide gene therapy. J. Clin. Invest. 2000, 105, 1161-1167.
6. Springer, C. J.; Niculescu-Duvaz, I. Gene-directed enzyme prodrug therapy. Anticancer Drug Development; Academic Press: New York, 2002; pp 137-152.
7. Gesson, J. P.; Jacquesy, J. C.; Mondon, M.; Petit, P.; Renoux, B. et al. Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anti-Cancer Drug Des. 1994, 9, 409-423.
8. Azoulay, M.; Florent, J.-C.; Monneret, C.; Gesson, J. P.; Jacquessy, J.-C. et al. Prodrugs of anthracycline antibiotics suited for tumor specific activation. Anti-Cancer Drug Des. 1995, 10, 441-450.
9. Farquhar, D.; Cherif, A.; Bakina, E.; Nelson, G. A. Intensely potent doxorubicin analogues: Structure-activity relationships. J. Med. Chem. 1998, 41, 965-972.
10. Schmidt, F.; Monneret, C. In vitro fluorine-19 nuclear magnetic resonance study of the liberation of antitumor nitrogen mustard from prodrugs. J. Chem. Soc., Perkin Trans. 1 2002, 1302-1308.
11. Niculescu-Duvaz, I.; Friedlos, F.; Niculescu-Duvaz, D.; Davies, L.; Springer, C. J. Prodrugs for antibody- and gene-directed enzyme prodrug therapies (ADEPT and GDEPT). Anti-Cancer Drug Des. 1999, 14, 517-538.
12. Hay, M. P.; Sykes, B. M.; Denny, W. A.; Wilson, W. R. A 2-nitroimidazole carbamate prodrug of 5-amino-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbonyl]-1, 2-dihydro-3H-benz[e]-indole amino-seco-CBI-TMI) for use with ADEPT and GDEPT. Bioorg. Med. Chem. Lett. 1999, 9, 2237-2242.
13. Hay, M. P.; Wilson, W. R.; Denny, W. R. Nitobenzyl carbamate prodrugs of enediynes for nitroreductase gene-directed enzyme prodrug therapy. Bioorg. Med. Chem. Lett. 1999, 9, 3417-3422.
14. Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Friedlos, F.; Martin, J.; Lehouritis, P. et al. Self-immolative nitrogen mustards prodrugs cleavable by carboxypeptidase G2 showing large cytotoxicity differentials in GDEPT. J. Med. Chem. 2003, 46, 1690-1705.
15. Sherwood, R. F.; Melton, R. G.; Alwan, S. M.; Hughes, P. Purification and properties of carboxypeptidase G2 Pseudonomas sp strain RS-16. European Journal of Biochemistry 1985, 148, 447-453.
16. Springer, C. J.; Antoniw, P.; Bagshawe, K. D.; Searle, F.; Bisset, G. M. F. et al. Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 1990, 33, 677-681.
17. Springer, C. J.; Niculescu-Duvaz, I.; Mauger, A. B.; Connors, T. A.; Burke, P. J. et al. The design of prodrugs for antibody directed enzyme prodrug therapy (ADEPT). New Antibody Technology and the Emergence of Useful Cancer Therapy; The Royal Society of Medecine Press: London, 1995; pp 75-77.
18. Dowell, R. I.; Springer, C. J.; Davies, D. H.; Hadley, E. M.; Burke, P. J. et al. New mustard prodrug for antibody-directed enzyme prodrug therapy: Alternative to amide link. J. Med. Chem. 1996, 39, 1100-1105.
19. Marais, R.; Spooner, R. A.; Light, Y.; Martin, J.; Springer, C. J. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 1996, 56, 4735-4742.
20. Marais, R.; Spooner, R. A.; Stribbling, S. M.; Light, Y.; Martin, J. et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat. Biotechnol. 1997, 15, 1373-1377.
21. Springer, C. J.; Antoniw, P.; Bagshawe, K. D.; Wilman, D. E. V. Comparison of half-lives and cytotoxicity of N-mesyloxyethyl- and N-chloroethyl-4-amino benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anticancer Drug Des. 1991, 6, 467-479.
22. Springer, C. J.; Niculescu-Duvaz, I.; Pedley, R. B. Novel prodrugs of alkylating agents derived from 2-fluoro- and 3-fluoro benzoic acids for antibody-directed enzyme prodrug therapy. J. Med. Chem. 1994, 37, 2361-2370.
23. Friedlos, F.; Davies, L.; Scanlon, I.; Ogilvie, L. M.; Martin, J. et al. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficay in two xenograft models. Cancer Res. 2002, 62, 1724-1729.
24. Niculescu-Duvaz, I.; Springer, C. J. Adamantylanyloxycarbonyl: a novel protecting group for phenols carrying strongly electron-withdrawing substituents. J. Chem. Res. (S) 1994, 242-243.
25. Springer, C. J.; Dowell, R.; Burke, P. J.; Hadley, E.; Davies, D. H. et al. Optimization of alkylating agent prodrug derived from phenol and aniline mustards: A new clinical candidates prodrug (ZD2767) for antibody-directed prodrug therapy (ADEPT). J. Med. Chem. 1995, 38, 5051-5065.
26. Niculescu-Duvaz, D.; Niculescu-Duvaz, I.; Friedlos, F.; Martin, J.; Spooner, R. et al. Self-immolative nitrogen mustard prodrugs for suicide gene therapy. J. Med. Chem. 1998, 41, 5297-5309.
27. Springer, C. J.; Niculescu-Duvaz, I. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs. Anti-Cancer Drug Des. 1995, 10, 361-372.